ArticleThe Prostate2025
A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic Accuracy Beyond PSA.
Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThis study aimed to evaluate the association between biochemical markers and prostate cancer (PCa) risk by analyzing patients with benign prostatic hyperplasia (BPH) and PCa. Additionally, the study sought to assess the diagnostic accuracy of a multimarker model compared to prostate-specific antigen (PSA) alone.
methodsA cross-sectional study was conducted with data from 2931 patients (1374 with BPH and 1557 with PCa) from the Prostate Cancer Data Set of the National Population Health Data Center. Biochemical markers, including PSA, apolipoproteins, lipid profiles, and metabolic markers (calcium and phosphate), were analyzed. Univariate and multivariate logistic regression analyses were performed to assess the associations with PCa risk. The diagnostic performance of the multimarker model was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsTotal PSA levels were significantly higher in PCa patients, and the free/total PSA ratio was lower (p < 0.001). Apolipoprotein A1, LDL cholesterol, calcium, and phosphate were also significantly associated with PCa risk (p < 0.001). The multivariate logistic regression model, incorporating multiple markers, showed improved diagnostic accuracy (AUC 0.731, 95% CI: 0.713-0.749), with sensitivity of 68.4% and specificity of 65.8%.
conclusionsCombining multiple biochemical markers with PSA enhances the diagnostic accuracy for PCa, offering additional predictive value. This multimarker approach has the potential to improve PCa screening and reduce unnecessary biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.